A systematic analysis of patient data combined with molecular dynamics simulations and in vitro drug screens have revealed structure–function relationships that, in retrospective analyses, correctly identified drug sensitivity in patients with non–small cell lung cancer harboring atypical oncogenic EGFR mutations.

You do not currently have access to this content.